Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results.
Journal: Blood advances
Published: December 02, 2024
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Journal: Haematologica
Published: July 10, 2023
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Journal: The Lancet. Haematology
Published: June 07, 2022
Pleiotropic effects of genistein in metabolic, inflammatory, and malignant diseases.
Journal: Nutrition reviews
Published: July 20, 2013
Risk factors for rising incidence of esophageal and gastric cardia adenocarcinoma.
Journal: Journal of gastrointestinal cancer
Published: February 26, 2013
Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma.
Journal: American journal of clinical oncology
Published: May 31, 2012
Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma.
Journal: Expert opinion on therapeutic targets
Published: May 25, 2012
Showing 1-7 of 7
Last Updated: 09/26/2026